Chugai Announces Co-Development and Co-Marketing Agreement with Taisho Pharmaceutical for the Antiresorptive Bisphosphonate R484.Tokyo, Japan, Sept 12, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) Newswire) - Chugai Pharmaceutical Co., Ltd. announced today that it has entered into an agreement with Taisho Pharmaceutical Taisho Pharmaceutical Co., Ltd. (大正製薬株式会社 Co., Ltd. to co-develop and co-market R484 (generic name generic name n. 1. The official nonproprietary name of a drug, under which it is licensed and identified by the manufacturer. 2. : ibandronic acid Ibandronic acid (INN) or ibandronate sodium (USAN), marketed under the trade names Boniva®, Bondronat® and Bonviva®, is a potent bisphosphonate drug used in the prevention and treatment of osteoporosis. ), a bisphosphonate which Chugai is currently developing in Japan for the treatment of osteoporosis. Under the agreement, Chugai will co-develop the compound with Taisho and co-market it with Taisho Toyama Pharmaceutical Co., Ltd., a subsidiary of Taisho. Chugai will receive an upfront fee and milestone payments from Taisho. R484, a bisphosphonate compound owned by Roche, demonstrates a strong inhibitory effect on bone resorption Bone resorption is the process by which osteoclasts break down bone and release the minerals, resulting in a transfer of calcium from bone fluid to the blood. The osteoclasts are multi-nucleated cells that contain numerous mitochondria and lysosomes. . A less frequent dosing and administration has been developed (for oral and injection) to improve convenience and compliance by reducing complicated restrictions when administering the medicine and to reduce the adverse reactions adverse reactions, n.pl unfavorable reactions resulting from administration of a local anesthetic; responsible factors include the drug used, concentration, and route of administration. often seen in oral bisphosphonate preparations, mainly reactions related to the gastrointestinal track. In Japan, a phase II clinical trial Noun 1. phase II clinical trial - a clinical trial on more persons than in phase I; intended to evaluate the efficacy of a treatment for the condition it is intended to treat; possible side effects are monitored phase II is ongoing for the oral formulation and a phase II clinical trail has been completed for the injectable formulation. Since there are an estimated 12 million osteoporosis patients in Japan, it is becoming increasingly important to develop a drug which increases bone mass and reduces the risk of bone fractures, while being easy to administer. R484 is expected to become a next generation osteoporosis treatment that improves compliance by decreasing the problems associated with the conventional bisphosphonates, and offers patients more choice of administration routes. Chugai and Taisho are determined to provide patients with access to this new osteoporosis treatment as early as possible, and believe the joint effort to develop R484 will accelerate the process. * Overseas, Roche and their co-development partner, GSK GSK GlaxoSmithKline plc (pharmaceutical company) GSK Glycogen Synthase Kinase GSK Gruppentraining Sozialer Kompetenzen (Germany) GSK Greenland Shark (FAO fish species code) , markets the product under the brand name Bonviva (Boniva in US) as a once-monthly oral formulation and a once-every-three-months injection formulation for the treatment of osteoporosis in post menopausal women. About Chugai Pharmaceutical Co., Ltd. Chugai Pharmaceutical Co., Ltd. (TSE See Tokyo Stock Exchange. TSE 1. See Tokyo Stock Exchange (TSE). 2. See Toronto Stock Exchange (TSE). : 4519) is one of Japan's leading research-based pharmaceutical companies with strengths in biotechnology products and in the therapeutic fields of oncology, renal diseases, cardiovascular diseases, bone/joint diseases and transplantation/infection/immunity. As a most important member of the Roche group, we aim to become a top Japanese pharmaceutical company by providing a continuous flow of innovative new medicines domestically and internationally. For more information, please visit www.chugai-pharm.co.jp. About Taisho Pharmaceutical Co Ltd. Taisho Pharmaceutical Co Ltd. (TSE: 4535) is Japan's leading producer of over-the-counter (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). ) drugs, and the number two OTC drug manufacturer in the world. Taisho is currently endeavoring to strengthen its independent R&D capabilities in the field of prescription pharmaceuticals, and also aggressively pursuing tie-ups with both Japanese and overseas companies. For more information, please visit www.taisho.co.jp/outline/index-e.htm. Source: Chugai Pharmaceutical Co., Ltd. Contact: Mamoru Togashi General Manager, Corporate Communications Dept. Tel:+81-3-3273-0881 Copyright [c] 2006 JCN Newswire. All rights reserved. A division of Japan Corporate News Network K.K. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion